Treatment with a custom-made vaccine combination was found to be safe and feasible for patients with bladder cancer, ...

Immune checkpoint inhibitors have shown a survival benefit in patients with metastatic urothelial cancer, so investigators trialed neoadjuvant nivolumab and ipilimumab in patients with muscle-invasive ...

Neoadjuvant mitomycin C before transurethral resection of bladder tumor (TURBT) showed a favorable safety profile in patients with non-muscle invasive bladder cancer (NMIBC). While an improvement in ...

Keeping its bladder clean, dry and mold-free between uses! That's where the DRYE device comes in, as it's a battery-powered fan designed specifically to dry hydration pack bladders. SUBSCRIBE ...

UGN-102 (intravesical mitomycin) induced a clinically meaningful complete response (CR) rate combined with acceptable tolerability among patients with recurrent low-grade intermediate-risk non-muscle ...

Early findings from Johnson & Johnson’s Phase IIb SunRISe-1 trial show the promise of TAR-200 in patients with Bacillus Calmette-Guérin–unresponsive, high-risk non–muscle-invasive bladder cancer, ...

UGN-102 is UroGen’s sustained-release formulation of mitomycin, being developed for recurrent low-grade, intermediate-risk, non-muscle-invasive bladder cancer (LG-IR-NMIBC). Among the 41 ...

“Complication rates were super low: just 3.7% for prostate surgeries, 1.9% for kidney surgeries, and 17.9% for bladder surgeries, all beating safety goals from years of research”. The company further ...

Pfizer has linked its PD-1 inhibitor to a 32% reduction in the risk of disease-related events in a phase 3 bladder cancer trial. But the study fell short of a clean sweep of positive outcomes ...

Among patients with non–muscle-invasive bladder cancer, neoadjuvant mitomycin demonstrated favorable safety. Among patients with non-muscle-invasive bladder cancer (NMIBC), neoadjuvant treatment with ...

UGN-102 is UroGen’s sustained-release formulation of mitomycin being developed for the treatment of recurrent low-grade intermediate-risk non-muscle invasive bladder cancer (LG-IR-NMIBC). "The median ...

Pfizer has shared the trial results with worldwide regulatory bodies in preparation for filing regulatory applications. Credit: © 2025 Pfizer. US-based ...